A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone

Inclusion Criteria: Subjects must satisfy all of the following criteria at the Screening Visit unless otherwise stated: * Males or females, of any race, between 18 and 55 years of age, inclusive. * Body mass index between 18.0 and 32.0 kg/m2, inclusive, and a total body weight \>50 kg. * In good health. * Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception. * Able to comprehend and willing to sign an ICF and to abide by the study restrictions. Exclusion Criteria: Subjects will be excluded from the study if they satisfy any of the following criteria at the Screening visit, unless otherwise stated: * Significant history or clinical manifestation of any major system disorder, as determined by the investigator (or designee). * History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator (or designee). * History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (cholecystectomy will not be allowed; uncomplicated appendectomy and hernia repair will be allowed). * History of alcoholism or drug/chemical abuse within 2 years prior to Check in (Day 1). * Abnormal laboratory values considered clinically significant by the investigator * Clinically significant abnormal 12 lead ECGs * Personal history of unexplained syncopal events, or family history of long QT syndrome or sudden unexplained death in a young person. * Pulse rate \<50 bpm or systolic blood pressure \<110 mmHg. * Alcohol consumption of \>21 units per week for males and \>14 units for females. * Positive urine drug screen or positive alcohol breath test result or positive urine drug screen. * Positive hepatitis panel and/or positive human immunodeficiency virus test. Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 30 days prior to dosing or 5 half lives (if known), whichever is longer, prior to dosing. * Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to dosing, unless deemed acceptable by the investigator (or designee). * Have previously completed or withdrawn from this study or any other study investigating omaveloxolone, and have previously received the investigational product. * Subjects who, in the opinion of the investigator (or designee), should not participate in this study.